Rushworth and collaborators demonstrated a decrease in NF-κB, ERK (extracellular signal-regulated kinase) and AKT activity in primary AML and AML cell lines following treatment with ibrutinib, leading to cell death and suggesting that BTK supports AML cell survival [163]. The gene discussed is AKT1; the disease is acute myeloid leukemia.